Sensitive LC-MS/MS-ESI method for simultaneous determination of montelukast and fexofenadine in human plasma: Application to a bioequivalence study

Biomedical Chromatography

Volumn 28, Issue 8, 2014, Pages 1048-1056

  Muppavarapu, Rajendraprasad ^a,b   Guttikar, Swati ^a   Rajappan, Manavalan ^b   Kamarajan, Kannan ^b   Mullangi, Ramesh ^c  

^a Veeda Clinical Research India   (India)

^b ANNAMALAI UNIVERSITY   (India)

^c JUBILANT BIOSYS LTD   (India)

Author keywords

Bioequivalence; Fexofenadine; Human plasma; LC MS MS; Method validation; Montelukast; Pharmacokinetics

Indexed keywords

PLASMA (HUMAN);

BIOEQUIVALENCE; BIOEQUIVALENCE STUDY; FEXOFENADINE; HUMAN PLASMAS; LC-MS-MS; LC.MS/MS; METHOD VALIDATIONS; MONTELUKAST; SIMPLE++; SIMULTANEOUS DETERMINATIONS;

ELECTROSPRAY IONIZATION;

ACETONITRILE; AMMONIUM FORMATE; FEXOFENADINE; MONTELUKAST; ACETIC ACID DERIVATIVE; QUINOLINE DERIVATIVE; TERFENADINE;

ADULT; ARTICLE; BIOEQUIVALENCE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG STABILITY; ELECTROSPRAY MASS SPECTROMETRY; FLOW RATE; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; LIQUID LIQUID EXTRACTION; MALE; MEASUREMENT ACCURACY; MEASUREMENT PRECISION; NORMAL HUMAN; PRACTICE GUIDELINE; QUANTITATIVE ANALYSIS; TANDEM MASS SPECTROMETRY; ANALOGS AND DERIVATIVES; BLOOD; CHEMISTRY; CROSSOVER PROCEDURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; SINGLE BLIND PROCEDURE; STATISTICAL MODEL; THERAPEUTIC EQUIVALENCE;

ACETATES; ADULT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; DRUG STABILITY; HUMANS; LINEAR MODELS; MALE; QUINOLINES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SINGLE-BLIND METHOD; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY; TERFENADINE; THERAPEUTIC EQUIVALENCY;

EID: 84904465281     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.3114     Document Type: Article

References (22)

1. Bharathi DV, Hotha KK, Jagadeesh B, Mullangi R and Naidu A. Quantification of montelukast, a selective cysteinyl leukotriene receptor (CysLT1) antagonist in human plasma by liquid chromatography-mass spectrometry: validation and its application to a human pharmacokinetic study. Biomedical Chromatography 2009; 23: 804-810.
2. Bharathi DV, Radharani K, Jagadeesh B, Ramulu G, Bhushan I, Naidu A and Mullangi R. LC-MS-MS assay for simultaneous quantification of fexofenadine and psuedoephedrine in human plasma. Chromatographia 2008; 67: 461-466.
3. Challa BR, Awen BZ, Chandu BR, Khagga M, Kotthapalli CB. Method development and validation of montelukast in human plasma by HPLC coupled with ESI-MS/MS: application to a bioequivalence study. Scientia Pharmaceutica 2010; 78: 411-422.
4. Cingi C, Gunhan K, Gage-White L and Unlu H. Efficacy of leukotriene antagonists as concomitant therapy in allergic rhinitis. Laryngoscope 2010; 120: 1718-1723.
5. EMA. Euopean Medicines Agency. Guideline on Validation of Bioanalytical Methods, 2011. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_ guideline/2011/08/WC500109686.pdf
6. Flynn CA, Alnouti Y and Reed GA. Quantification of the transporter substrate fexofenadine in cell lysates by liquid chromatography/tandem mass spectrometry. Rapid Communications in Mass Spectrometry 2011; 25: 2361-2366.
7. Fu I, Woolf EJ and Matuszewski BK. Determination of fexofenadine in human plasma using 96-well solid phase extraction and HPLC with tandem mass spectrometric detection. Journal of Pharmaceutical and Biomedical Analysis 2004; 35: 837-846.
8. Guo D, Zou J, Zhu Y, Lou S, Fan H and Qin Q. Measurement of fexofenadine concentration in micro-sample human plasma by a rapid and sensitive LC-MS/MS employing protein precipitation: application to a clinical pharmacokinetic study. Biomedical Chromatography 2010; 24: 335-341.
9. Hofmann U, Seiler M, Drescher S and Fromm MF. Determination of fexofenadine in human plasma and urine by liquid chromatography-mass spectrometry. Journal of Chromatography B 2002; 766: 227-233.
10. Isleyen EAO, Ozden T, Ozilhan S and Taptan S. Quantitative determination of fexofenadine in human plasma by HPLC-MS. Chromatographia 2007; 66: S109-S113.
11. Jones TR, Labelle M, Belley M, Champion E, Charette L, Evans J, Ford-Hutchinson AW, Gauthier JY, Lord A, Masson P, McAuliffe M, McFarlane CS, Metters KM, Pickett C, Pichuta H, Rochette C, Rodger IW, Swayer N, Yoyng RN, Zamboni R and Abraham WM. Pharmacology of montelukast sodium (Singulair), a potent and selective leukotriene D4 receptor antagonist. Canadian Journal of Physiology and Pharmacology 1995; 73: 191-201.
12. Liu F, He L, Ren J, Yang H and Zaho H. Determination of montelukast in human plasma by LC-MS/MS. Chinese Journal of Pharmaceutics 2012; 43: 50-52.
13. Nirogi RV, Kandikere VN, Shukla M, Mudigonda K, Maurya S and Komarneni P. Simultaneous quantification of fexofenadine and pseudoephedrine in human plasma by liquid chromatography/tandem mass spectrometry with electrospray ionization: method development, validation and application to a clinical study. Rapid Communications in Mass Spectrometry 2006; 20: 3030-3038.
14. Nirogi RV, Kandikere VN, Shukla M, Mudigonda K, Maurya S and Komarneni P. Quantification of fexofenadine in human plasma by liquid chromatography coupled to electrospray tandem mass spectrometry using mosapride as internal standard. Biomedical Chromatography 2007; 21: 209-216.
15. Papp R, Luk P, Mullett WM and Kwong E. A rapid and sensitive method for the quantitation of montelukast in sheep plasma using liquid chromatography/tandem mass spectrometry. Journal of Chromatography B 2007; 858: 282-286.
16. Peters-Golden M and Sampson AP. Cysteinyl leukotriene interactions with other mediators and with glucocorticosteroids during airway inflammation. Journal of Allergy and Clinical Immunology 2003; 111: 537-542.
17. Simpson K and Jarvis B. Fexofenadine: a review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria. Drugs 2000; 59: 301-321.
18. SINGULAIR, 2008. http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021409s026lbl.pdf
19. Stanton ML, Joy MS and Frye RF. Validation and application of a liquid chromatography- tandem mass spectrometric method for quantification of the drug transport probe fexofenadine in human plasma using 96-well filter plates. Journal of Chromatography B 2010; 878: 497-501.
20. Teng GS, Teng LS, Wu Y, Tang YB, Liu LY and Gu JK. Rapid and sensitive LC-MS/MS method for quantification of fexofenadine in human plasma - application to a bioequivalence study in Chinese volunteers. Chemical Research in Chinese Universities 2007; 23: 514-517.
21. US DHHS, FDA, CDER and CVM. Guidance for Industry: Bioanalytical Method Validation. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research and Center for Veterinary Medicine: Rockville, MD, 2001.
22. Yamane N, Tozuka Z, Sugiyama Y, Tanimoto T, Yamazaki A and Kumagai Y. Microdose clinical trial: quantitative determination of fexofenadine in human plasma using liquid chromatography/electrospray ionization tandem mass spectrometry. Journal of Chromatography B 2007; 858: 118-128.